ACT protocols employ either tumour-infiltrating lymphocytes (TILs) grown out from tumours in the presence of interleukin-2, or chimeric antigen receptor (CAR)-T cells, which are genetically engineered T cells expressing a synthetic receptor that redirects cytotoxicity towards target antigens. Here, IL2 is linked to neoplasm.